浏览全部资源
扫码关注微信
- Journal Information
- Archive
- Submission
- For Reviewers
- Statement and Policies
Study on the mechanism of Yishen tongluo formula improving abnormal lipid metabolism based on SREBPs pathway
- ZHONGGUO YAOFANG Vol. 34, Issue 23, Pages: 2835-2840(2023)
- 作者机构：
1.河南中医药大学中医药科学院，郑州 450046
2.马来西亚管理与科技大学国际学术部，马来西亚 雪兰莪州 莎阿南市 47300
- 作者简介：
- 基金信息：
DOI：10.6039/j.issn.1001-0408.2023.23.04
CLC： R965Published：15 December 2023，
Received：09 May 2023，
Revised：29 October 2023，
扫 描 看 全 文
赵靓,张效威,谢治深等.基于SREBPs通路的益肾通络方改善脂质代谢异常作用机制研究 Δ[J].中国药房,2023,34(23):2835-2840.
ZHAO Liang,ZHANG Xiaowei,XIE Zhishen,et al.Study on the mechanism of Yishen tongluo formula improving abnormal lipid metabolism based on SREBPs pathway[J].ZHONGGUO YAOFANG,2023,34(23):2835-2840.
赵靓,张效威,谢治深等.基于SREBPs通路的益肾通络方改善脂质代谢异常作用机制研究 Δ[J].中国药房,2023,34(23):2835-2840. DOI： 10.6039/j.issn.1001-0408.2023.23.04.
ZHAO Liang,ZHANG Xiaowei,XIE Zhishen,et al.Study on the mechanism of Yishen tongluo formula improving abnormal lipid metabolism based on SREBPs pathway[J].ZHONGGUO YAOFANG,2023,34(23):2835-2840. DOI： 10.6039/j.issn.1001-0408.2023.23.04.
摘要
目的
2
基于固醇调节元件结合蛋白（SREBPs）通路探究益肾通络方改善脂质代谢异常的作用机制。
方法
2
以C57BLKS/J（
db
/
db
）小鼠为模型动物、 C57BLKS/J（
db
/
m
）小鼠为正常对照，通过测定小鼠肝脏系数及血清中总胆固醇（TC）、甘油三酯（TG）、低密度脂蛋白（LDL）、高密度脂蛋白（HDL）含量，观察小鼠肝组织脂肪变性和脂质蓄积情况，测定小鼠肝组织中SREBP-1、SREBP-2蛋白和
Srebp-1c
、
Srebp-2
及其下游脂质代谢相关靶基因（
Fasn
、
Acc1
、
Scd5
、
Fads1
、
Hmgcr
、
Dhcr24
、
Insig-1
、
Fdps
）的mRNA转录水平，来考察1、2.5、5 g/kg益肾通络方改善
db
/
db
小鼠脂质代谢异常的作用机制。以低脂培养的人肝癌细胞HepG2为体外脂质代谢异常细胞模型，以25-HC（SREBPs抑制剂，10 μmol/L）为抑制剂对照，考察125、250、500 μg/mL益肾通络方干预24 h后对细胞中SREBP-1、SREBP-2蛋白和
SREBP-1c、SREBP-2
其下游脂质代谢相关靶基因mRNA转录水平的影响，进行体外机制验证。
结果
2
1、2.5、5 g/kg益肾通络方均可显著降低模型小鼠TC、TG、LDL水平，显著降低肝组织脂滴阳性面积百分比、肝脏系数，显著下调肝组织中Pre-SREBP-1、n-SREBP-1、Pre-SREBP-2、n-SREBP-2蛋白以及
Srebp-1c
、
Srebp-2
及其下游靶基因的mRNA转录水平，并可显著升高HDL水平，差异均有统计学意义（
P
＜0.05或
P
＜0.01）。体外细胞实验中，125、250、500 μg/mL益肾通络方作用24 h后细胞中上述蛋白及基因的表达的变化与动物实验一致，且抑制剂对照与250、500 μg/mL益肾通络方给药后细胞中上述蛋白和基因表达水平相比差异均无统计学意义（
P
＞0.05）。
结论
2
益肾通络方可能通过调控转录因子SREBPs表达，进而抑制脂肪酸及胆固醇合成相关基因的高表达，促进TC、TG的降解，改善脂质代谢异常，抑制脂质蓄积，从而发挥降脂作用。
Abstract
OBJECTIVE
2
To explore the mechanism of Yishen tongluo formula （YSTLF） in improving abnormal lipid metabolism based on the sterol regulatory element binding proteins （SREBPs） pathway.
METHODS
2
Using C57BLKS/J （
db
/
db
） mice as model and C57BLKS/J （
db
/
m
） mice as normal control， the mechanism of 1， 2.5 and 5 g/kg YSTLF improving abnormal lipid metabolism of
db
/
db
mice was investigated by determining the liver coefficient， the contents of serum total cholesterol （TC）， triglyceride （TG）， low-density lipoprotein （LDL） and high-density lipoprotein （HDL）， observing steatosis and lipid accumulation in liver tissue of mice， detecting the protein expressions of SREBP-1 and SREBP-2 as well as mRNA transcription levels of
Srebp-1c
，
Srebp-2
and their downstream lipid metabolism-related target genes （
Fasn
，
Acc1
，
Scd5
，
Fads1
，
Hmgcr
，
Dhcr24
，
Insig-1
，
Fdps
） in liver tissue of mice. Using low-fat cultured human liver cancer cell HepG2 as an
in vitro
cell model for abnormal lipid metabolism， and 25-HC （SREBPs inhibitor， 10 μmol/L） as the control， the effects of 125， 250 and 500 μg/mL YSTLF on protein expressions of SREBP-1 and SREBP-2 as well as mRNA transcription of
SREBP-1c
，
SREBP-2
and their downstream lipid metabolism-related target genes were investigated to verify the mechanism
in vitro
.
RESULTS
2
1， 2.5， 5 g/kg YSTLF significantly reduced the levels of TC， TG and LDL， the percentage of lipid droplet-positive region in liver tissue and liver coefficient， significantly down-regulated protein expressions of Pre-SREBP-1， n-SREBP-1， Pre-SREBP-2 and n-SREBP-2， and mRNA transcription of
Srebp-1c， Srebp-2
and their downstream target genes in liver tissue， while significantly increased HDL level， with statistical significance （
P
＜0.05 or
P
＜0.01）. In the cell experiment
in vitro
， the expressions of the above-mentioned proteins and genes in the cells treated with YSTLF at 125， 250 and 500 μg/mL for 24 hours were consistent with those in the animal experiment； there was no significant difference in the expressions of the above-mentioned proteins and genes between inhibitor control group and 250， 500 μg/mL YSTLF groups （
P
＞0.05）.
CONCLUSIONS
2
YSTLF can regulate the expression of transcription factor SREBPs， so as to inhibit the high expression of fatty acid and cholesterol synthesis-related genes， promote the degradation of TC and TG， improve the abnormality of lipid metabolism and inhibit lipid accumulation， thus playing the role of lipid-lowering.
关键词
益肾通络方脂质代谢异常固醇调节元件结合蛋白脂质蓄积转录因子
Keywords
abnormal lipid metabolismsterol regulatory element binding proteinslipid accumulationtranscription factors
references
DINCER N，DAGEL T，AFSAR B，et al.The effect of chronic kidney disease on lipid metabolism[J].Int Urol Nephrol，2019，51（2）：265-277.
BUZZETTI E，PINZANI M，TSOCHATZIS E A. The multiple-hit pathogenesis of non-alcoholic fatty liver di- sease （NAFLD）[J]. Metabolism，2016，65（8）：1038-1048.
ROSQVIST F，IGGMAN D，KULLBERG J，et al. Overfeeding polyunsaturated and saturated fat causes distinct effects on liver and visceral fat accumulation in humans[J]. Diabetes，2014，63（7）：2356-2368.
DEBOSE-BOYD R A，YE J. SREBPs in lipid metabolism，insulin signaling，and beyond[J]. Trends Biochem Sci，2018，43（5）：358-368.
SU L，ZHOU L K，CHEN F J，et al. Cideb controls sterol-regulated ER export of SREBP/SCAP by promoting cargo loading at ER exit sites[J]. EMBO J，2019，38（8）：e100156.
SOZEN E，DEMIREL-YALCINER T，SARI D，et al. Deficiency of SREBP1c modulates autophagy mediated lipid droplet catabolism during oleic acid induced steatosis[J]. Metabol Open，2021，12：100138.
GUO C S，CHI Z X，JIANG D L，et al. Cholesterol homeostatic regulator SCAP-SREBP2 integrates NLRP3 inflammasome activation and cholesterol biosynthetic signaling in macrophages[J]. Immunity，2018，49（5）：842-856.e7.
GARCÍA-GARCÍA A B，MARTÍNEZ-HERVÁS S，VERNIA S，et al. A very rare variant in SREBF2，a possible cause of hypercholesterolemia and increased glycemic levels[J]. Biomedicines，2022，10（5）：1178.
HOWE V，SHARPE L J，PRABHU A V，et al. New insights into cellular cholesterol acquisition：promoter analysis of human HMGCR and SQLE，two key control enzymes in cholesterol synthesis[J]. Biochim Biophys Acta Mol Cell Biol Lipids，2017，1862（7）：647-657.
PANG W Q，WANG D，ZUO Z H，et al. Kidney bean fermented broth alleviates hyperlipidemic by regulating serum metabolites and gut microbiota composition[J]. Nutrients，2022，14（15）：3202.
WANG L，ZHENG W，YANG J X，et al. Mechanism of Astragalus membranaceus alleviating acquired hyperlipi- demia induced by high-fat diet through regulating lipid metabolism[J]. Nutrients，2022，14（5）：954.
张明昊，高一盈，董文霞，等.复方丹参片对高脂血症模型大鼠血脂水平的改善及肾功能保护作用机制研究[J].中国药房，2022，33（7）：818-824.
ZHANG M H，GAO Y Y，DONG W X，et al. Study on the improvement of Compound Danshen tablets on blood lipid levels and the mechanism of protecting renal functions in hyperlipidemia model rats[J]. China Pharm，2022，33（7）：818-824.
ZHANG X W，ZHAO L，XIANG S X，et al. Yishen Tong- luo formula alleviates diabetic kidney disease through regulating Sirt6/TGF-β1/Smad2/3 pathway and promoting degradation of TGF-β1[J]. J Ethnopharmacol，2023，307：116243.
LI Y，GONG W Q，LIU J，et al. Angiopoietin-like protein 4 promotes hyperlipidemia-induced renal injury by down-regulating the expression of ACTN4[J]. Biochem Biophys Res Commun，2022，595：69-75.
XIE Z S，LI E W，GAO G，et al. Zexie Tang targeting FKBP38/mTOR/SREBPs pathway improves hyperlipi- demia[J]. J Ethnopharmacol，2022，290：115101.
TRINDADE B C，CEGLIA S，BERTHELETTE A，et al. The cholesterol metabolite 25-hydroxycholesterol restrains the transcriptional regulator SREBP2 and limits intestinal IgA plasma cell differentiation[J]. Immunity，2021，54（10）：2273-2287.e6.
BROWN M S，GOLDSTEIN J L. The SREBP pathway：regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor[J]. Cell，1997，89（3）：331-340.
0
Views
2
下载量
0
CSCD
- L-PDFDownload
- WORDDownload
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
- Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号
公网安备50010302001817 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.